230 related articles for article (PubMed ID: 31380588)
1. Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients.
Zhang Q; Li G; Yu Y; Qiu C; Zheng J; Zhang H; Zhang M; Song Z; Yang Y; Du X; Hong J; Lu J; Li N; Tang Q; Xu L; Wang X; Huang Y; Zhang J; Chen Z; Zhang W
J Viral Hepat; 2019 Jul; 26 Suppl 1():59-68. PubMed ID: 31380588
[TBL] [Abstract][Full Text] [Related]
2. Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos(t)ide analog treatment.
Li G; Zhang Q; Yu Y; Qiu C; Zhang H; Zhang M; Song Z; Yang Y; Hong J; Lu J; Li N; Tang Q; Xu L; Wang X; Zhang W; Chen Z
J Viral Hepat; 2019 Jul; 26 Suppl 1():50-58. PubMed ID: 31380590
[TBL] [Abstract][Full Text] [Related]
3. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B.
Liu Y; Li H; Yan X; Wei J
J Viral Hepat; 2019 Jul; 26 Suppl 1():69-76. PubMed ID: 31380585
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
6. Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa.
Wang YX; Zheng SM; Zhang Y; Qin JP; Lin H; Liu XC; Shen CF; Jiang MD
Scand J Gastroenterol; 2013 Feb; 48(2):213-7. PubMed ID: 23234601
[TBL] [Abstract][Full Text] [Related]
7. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
9. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
Sun J; Ding H; Chen G; Wang G; Wei L; Zhang J; Xie Q; Wan M; Tang H; Chen S; Gao Z; Wang Y; Zhang D; Huang W; Sheng J; Ning Q; Yang D; Lu J; Pan C; Yang Y; Wang J; Sun C; Wang Q; Hou J
BMC Gastroenterol; 2019 May; 19(1):65. PubMed ID: 31046700
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
11. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
12. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
13. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
14. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure.
Weng M; Zeng WZ; Wu XL; Zhang Y; Jiang MD; Wang Z; Zhou DJ; He X
Virol J; 2013 Sep; 10():277. PubMed ID: 24010768
[TBL] [Abstract][Full Text] [Related]
15. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
Wei W; Wu Q; Zhou J; Kong Y; You H
Int J Environ Res Public Health; 2015 Aug; 12(8):10039-55. PubMed ID: 26308024
[TBL] [Abstract][Full Text] [Related]
16. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.
Huang J; Zhang K; Chen W; Liao J; Luo X; Chen R
Sci Rep; 2017 Oct; 7(1):13383. PubMed ID: 29042662
[TBL] [Abstract][Full Text] [Related]
17. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
[TBL] [Abstract][Full Text] [Related]
18. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
[TBL] [Abstract][Full Text] [Related]
19. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
